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Abstract
This article explores the evolving evidence supporting the provision of opioid maintenance therapies
to incarcerated populations.
As of December 2008, approximately 10 million people
around the world were incarcerated [1]. The United
States has the highest incarceration rate in the world [1],
with more than 2 million incarcerated adults [2], and
roughly 50% of them suffer from substance abuse or
dependence [3]. It follows that illicit drug use in
prisoners is a huge problem for society as it is linked
with the spreading of HIV and other infectious diseases,
increased recidivism, and death. However, few prisoners
who need treatment for substance abuse actually receive
it, with only about 15% of US prisoners who used drugs
in the 30 days prior to incarceration receiving formal
substance abuse treatment from trained clinicians [3]. A
significant portion of US incarcerated adults have
histories of heroin addiction: probably somewhere
between 12% and 15% of all prisoners [4,5] and nearly
25% of prisoners in state facilities (i.e., those convicted
of more serious offences) [6]. Left untreated or under-
treated, withdrawal symptoms and cravings combined
with the general availability of drugs in prison contribute
to inmates’ drug use [7]. The result is the spreading of
infectious diseases such as HIV [11,12] through ‘needle
sharing’, creating a large-scale public health problem [8].
Heroin use, in particular, also increases recidivism [13]
and mortality [14].
Evidence-based research [9,10] clearly demonstrates that
opioid maintenance therapy using methadone or bupre-
norphine effectively reduces heroin use. Because of this,
opioid maintenance therapies are currently recom-
mended by the World Health Organization and the
United Nations for both general and incarcerated
[15,16,17] populations. As of 2008, although opioid
maintenance therapies were available to the general
population in 66 countries, only 29 countries had
implemented any opioid maintenance therapies in jails
or prisons, with only pilot programs and/or limited
availability in many places [18-20].
This underprovision of treatment probably stems from
the opinion that people who use illegal substances have
broken the law and require punishment for misbehavior
rather than treatment. However, advances in three
related areas have made this argument less tenable.
Firstly, there has been a realization that substance use
disorders are chronic, brain-based medical disorders
with high relapse rates [21,22]; secondly, there has been
an increasing emphasis on evidence-based treatments in
health care; and thirdly, recent evidence-based research
has demonstrated that opioid maintenance therapies
reduce heroin use in incarcerated populations as well as
the general population. The conceptualization of sub-
stance use disorders as chronic medical conditions [23] is
supported by molecular and imaging studies that have
led the scientific community to view them as brain
disorders with genetic contributions [22,24]; this has
increased support for the chronic disease model and
necessitated efficacious biological treatments.
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’Studies with inmates, as well as over 20 years of
experience of a methadone maintenance therapy pro-
gram at Rikers Island jail in New York, have added to
opioid maintenance therapy’s already extensive evidence
base of data on the general population. The first
randomized controlled trial of methadone maintenance
with prisoners, conducted in 1968 [25], demonstrated
impressive results postrelease. Offenders who received
methadone maintenance before and after release were
significantly less likely to use heroin or reoffend than
wait-list controls. The Key Extended Entry Program
(KEEP) at Rikers Island has been providing methadone
maintenance during incarceration and dedicated treat-
ment program slots postrelease since 1987 [26].
More recent studies have also had encouraging results. A
US randomized trial of methadone maintenance initiated
before or just after release from prison demonstrated
encouraging results [27]. Patients were randomized to (a)
counseling during incarceration with instructions to seek
treatment upon release; (b) counseling during incarcera-
tion with facilitated referral to methadone maintenance
upon release; or (c) counseling and methadone main-
tenance during incarceration, which was continued in the
community upon release. Results 12 months after release
demonstrated that participants receiving counseling and
methadone while in prison were more likely than both of
the other groups to be retained in treatment and were less
likelytohaveopioid-orcocaine-positiveurinesthanthose
in the counseling-only group [28]. An Australian rando-
mized controlled trial also demonstrated reduced rates of
heroin use, injection drug use, and syringe sharing among
patients receiving methadone maintenance, relative to
wait-list controls [29]. Older research evaluations of
methadone maintenance programs during incarceration
in Australia [30,31], the United States [32], and Canada
[33] have also had positive results. A recent systematic
review demonstrated that patients receiving opioid main-
tenance therapies during incarceration had a 55–75%
reductionininjectiondruguseanda47–73%reductionin
needle sharing, relative to controls [34].
Although there have been fewer studies of buprenor-
phine treatment than methadone maintenance with
incarcerated patients, results are promising. A rando-
mized controlled trial conducted at the Rikers Island jail
in New York [35] compared methadone maintenance to
buprenorphine treatment; both treatments were given
during incarceration in jail and postrelease. While there
were no differences in reported drug use or re-arrest after
incarceration, buprenorphine treatment patients were
significantly less likely than methadone maintenance
patients to withdraw from treatment in jail and had
significantly higher attendance at postrelease care.
A feasibility study of buprenorphine treatment provided
during incarceration and postrelease in Puerto Rico
demonstrated that those who completed treatment were
significantly less likely than untreated peers to have
opioid-positive urine and be involved in self-reported
crime [36]. Another study is currently underway in the
United States [37].
The findings reviewed here are important because they
provide evidence that opioid maintenance therapies for
prisoners reduce drug use and act as a disease prevention
measure. Now armed with the evidence, we can hope to
change attitudes amongst the public and those working
in the legal and prison systems to reduce the stigma
associated with both addiction and medication-assisted
treatments, to change laws and practices on interna-
tional, national, and local levels, and to implement
medication-assisted treatments with extensive follow up/
aftercare for incarcerated individuals with opioid depen-
dence. There is a continuing need for well-designed
research studies, preferably randomized controlled trials,
to further examine the efficacy of opioid maintenance
therapies within specific incarcerated populations because
different populations could respond to treatment differ-
ently and there could be a need to adapt the treatment to
work better with a specific population.
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